Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amirhossein Ahmadieh Yazdi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Truncated ferritin nanocages: enhanced drug encapsulation and delivery

    by Amirhossein Ahmadieh-Yazdi, Mohammad Ahmadyousefi, Niloofar Shokrollah, Meysam Soleimani

    Nanomedicine has emerged as a promising strategy to mitigate the drawbacks of chemotherapy by enabling targeted drug delivery. Protein nanocages, particularly ferritin, have gained attention due to their unique structural properties and biocompatibility. Herein, the development and characterization of truncated maize ferritin 1 (T-ZmFer1) nanocages for enhanced drug delivery are reported, achieved by removing the E-helix through excision of 17 amino acids from the C-terminus of the protein. T-ZmFer1 was expressed in Escherichia coli Bl21 (DE3) and optimized to enhance soluble protein expression. Purified T-ZmFer1 nanocages exhibited a size of 18.17 nm with a zeta potential of −19.9 mV, indicating well-defined structural characteristics. Drug encapsulation studies revealed a significant increase in encapsulation capacity for T-ZmFer1 nanocages compared to intact ZmFer1 nanocages, with a loading efficiency of ≈76 DOX/protein. Moreover, in vitro drug release profiles demonstrated controlled release kinetics for T-ZmFer1 nanocages, with pH-dependent release behavior. Cytotoxicity assays in SKBR3 cells showed comparable efficacy between DOX-loaded T-ZmFer1 and ZmFer1 nanocages, with T-ZmFer1 nanocages exhibiting superior cytotoxicity at 1 μM DOX concentration. This study underscores the potential of T-ZmFer1 nanocages as versatile drug delivery systems for cancer therapy, offering enhanced biocompatibility and therapeutic efficacy, thus contributing to the advancement of nanomedicine.

  • Open Access

    Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy

    by Maryam Sahlolbei, Amirhossein Ahmadieh-Yazdi, Mohadeseh Rostamipoor, Hamed Manoochehri, Hanie Mahaki, Hamid Tanzadehpanah, Naser Kalhor, Mohsen Sheykhhasan

    Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of cancer immunotherapy, offering a targeted approach to combat various hematologic malignancies. In this treatment, the patient’s genetically modified T cells are extracted and transformed to produce chimeric antigen receptors (CARs) that are exclusive to cancer cells. These altered T cells identify, attach to, and destroy cancer cells when they are reinfused back into the patient, offering a customized course of therapy. While the CAR T-cell therapy’s clinical success has been most evident in cases of acute lymphoblastic leukemia and certain types of lymphomas, ongoing research aims to extend its applicability to solid tumors. Despite its promise, challenges like cytokine release syndrome and the high cost of treatment remain. Nonetheless, CAR T-cell therapy heralds a new era in cancer treatment, offering a potentially curative approach for patients with otherwise refractory diseases.


  • Open Access

    Multifunctional nanostructures: Intelligent design to overcome biological barriers

    by Mehdi Azizi, Rana Jahanban-Esfahlan, Hadi Samadian, Masoud Hamidi, Khaled Seidi, Alireza Dolatshahi-Pirouz, Amirhossein Ahmadieh Yazdi, Amin Shavandi, Sophie Laurent, Mahsa Be Omide Hagh, et al.


  • Open Access

    FLVCR1-AS1 and FBXL19-AS1: Two Putative lncRNA Candidates in Multiple Human Cancers

    by Mohsen Sheykhhasan, Hamid Tanzadehpanah, Amirhossein Ahmadieh Yazdi, Hanie Mahaki, Reihaneh Seyedebrahimi, Mohammad Akbari, Hamed Manoochehri, Naser Kalhor, Paola Dama

    (1) Background: Mounting evidence supports the idea that one of the most critical agents in controlling gene expression could be long non-coding RNAs (lncRNAs). Upregulation of lncRNA is observed in the different processes related to pathologies, such as tumor occurrence and development. Among the crescent number of lncRNAs discovered, FLVCR1-AS1 and FBXL19-AS1 have been identified as oncogenes in many cancer progression and prognosis types, including cholangiocarcinoma, gastric cancer, glioma and glioblastoma, hepatocellular carcinoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, and osteosarcoma. Therefore, abnormal FBXL19-AS1 and FLVCR1-AS1 expression affect a variety of cellular activities, including metastasis, aggressiveness, and proliferation; (2) Methods: This study was searched via PubMed and Google Scholar databases until May 2022; (3) Results: FLVCR1-AS1 and FBXL19-AS1 participate in tumorigenesis and have an active role in impacting several signaling pathways that regulate cell proliferation, migration, invasion, metastasis, and EMT; (4) Conclusions: Our review focuses on the possible molecular mechanisms in a variety of cancers regulated by FLVCR1-AS1 and FBXL19-AS1. It is not surprising that there has been significant interest in the possibility that these lncRNAs might be used as biomarkers for diagnosis or as a target to improve a broader range of cancers in the future.